One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy

<p> <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/immunoglobulin-a-nephropathy" target="_blank">Immunoglobulin A nephropathy</a> (IgAN) is a serious, progressive, immune complex–mediated <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/nephropathy" target="_blank">kidney disease</a>. Being a rare disease, a key challenge for the evaluation of potential new <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/therapeutic-procedure" target="_blank">treatments</a> for IgAN is that the progression to end-stage kidney disease typically evolves over many years. Therefore, there is interest in defining earlier surrogate endpoints to serve as reliable predictors of treatment effect on long-term IgAN kidney outcomes. [Opening paragraph]</p>